

NOVARTIS AG

ISIN: CH0012005267

WKN: 1200526

Overview


| | |
|------------|-------|
| -- | |
| Price | - |
| Difference | - (-) |

| | |
|---------------------------|------------------------------------|
| General attributes | |
| ISIN | CH0012005267 |
| Symbol | NOVN |
| Exchange | - |
| Currency | - |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 179,816 EUR |
| Benchmark | SWISS MARKET INDEX |

| | |
|--------------------|---|
| Market data | |
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | - |
| High | - |
| Low | - |
| Close (prev. day) | - |
| VWAP | - |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | - |
| Last size | - |

| | |
|----------------------------|----|
| Futures and Options | |
| Related Futures | 30 |
| Related Options | - |

| | |
|-----------------------------|---|
| PDF Downloads | |
| Company report: NOVARTIS AG |  |



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| | on instrument | on sector | on market | |
|--|---------------|---|-----------------------|---|
| | Date | | Headline | Download |
| | 2024/04/26 |  | Global Equity Ratings |  |
| | 2024/04/03 |  | Global Equity Ratings |  |
| | 2024/03/13 |  | Global Equity Ratings |  |
| | 2024/02/22 |  | Global Equity Ratings |  |
| | 2024/02/14 |  | Global Equity Ratings |  |

Details

| | |
|------------|-------|
| -- | |
| Price | - |
| Difference | - (-) |

| General attributes | |
|--------------------|------------------------------------|
| ISIN | CH0012005267 |
| Symbol | NOVN |
| Exchange | - |
| Currency | - |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 179,816 EUR |
| Benchmark | SWISS MARKET INDEX |

| Market data | |
|-------------------|---|
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | - |
| High | - |
| Low | - |
| Close (prev. day) | - |
| VWAP | - |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | - |
| Last size | - |

| Performance and Risk | | | |
|----------------------|------|------|------|
| | 6m | 1Y | 3Y |
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 0.73 | 0.87 | 0.78 |
| Volatility | - | - | - |



Information about previous performance does not guarantee future performance.
Source: FactSet

| Price data | |
|---|--------|
| Ø price 5 days Ø volume 5 days (pcs.) | -- (-) |
| Ø price 30 days Ø volume 30 days (pcs.) | -- (-) |
| Ø price 100 days Ø volume 100 days (pcs.) | -- (-) |
| Ø price 250 days Ø volume 250 days (pcs.) | -- (-) |
| YTD High date | -- (-) |
| YTD Low date | -- (-) |
| 52 Weeks High date | -- (-) |
| 52 Weeks Low date | -- (-) |

| All listings for NOVARTIS AG | | | | | | |
|---|------------|-------|-----------|-----------------------|------------------|--|
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades | |
| Stuttgart | 2019/06/28 | 21:58 | 80.10 EUR | 0.04 | 11 | |
| SIX Swiss Exchange | 2024/05/07 | 17:31 | 89.78 CHF | 217.63 | 10,456 | |
| London Stock Exchange European Trade Reporting | 2024/05/07 | 17:20 | 89.63 CHF | 0.05 | 11 | |
| Hanover | 2019/06/28 | 08:01 | 80.10 EUR | 0.00 | 2 | |
| Hamburg | 2019/06/28 | 14:05 | 80.19 EUR | 0.08 | 4 | |

| | | | | | | | |
|------------------------|----------------|-------|-------|-----|-------|--|----|
| | 06/28 | | | | | | |
| Frankfurt | 2019/ 06/28 | 19:57 | 80.16 | EUR | 0.13 | | 13 |
| FINRA other OTC Issues | 2024/ 05/06 | 15:30 | 95.23 | USD | 13.67 | | 6 |
| Duesseldorf | 2019/ 06/28 | 14:08 | 80.18 | EUR | 0.00 | | 2 |
| Berlin | 2019/ 06/28 | 18:45 | 80.40 | EUR | 0.00 | | 16 |

Company profile

Company Logo



Contact Details

NOVARTIS AG

--

Lichtstrasse 35 - 4056 Basel

Telefon: +41-61-324-11-11

Fax: +

E-mail: -

PDF Downloads

Company report: NOVARTIS AG



Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Members of Management Board

| | |
|-------------------------|-------------------------------|
| Vasant (Vas) Narasimhan | Chairman of Managing Board |
| Klaus Moosmayer | Member of Executive Committee |
| Steffen Lang | Member of Executive Committee |
| Aharon Gal | Member of Executive Committee |
| Fiona H. Marshall | Member of Executive Committee |
| Harry Kirsch | Member of Executive Committee |
| Karen Hale | Member of Executive Committee |
| Kees Rokx | Member of Executive Committee |
| Lutz Hegemann | Member of Executive Committee |
| Michelle Weese | Member of Executive Committee |
| Patrick Horber | Member of Executive Committee |
| Rob Kowalski | Member of Executive Committee |
| Shreeram Aradhye | Member of Executive Committee |
| Victor Bulto | Member of Executive Committee |

Board of directors

| | |
|---------------------|--------------------------------------|
| Charles Sawyers | Member of the administrative board |
| Nancy Andrews | Member of the administrative board |
| Simon Moroney | Member of the administrative board |
| Ana de Pro Gonzalo | Member of the administrative board |
| Bridgette Heller | Member of the administrative board |
| Daniel Hochstrasser | Member of the administrative board |
| Frans van Houten | Member of the administrative board |
| John Young | Member of the administrative board |
| Mary Doherty | Member of the administrative board |
| Patrice Bula | Member of the administrative board |
| Ton Büchner | Member of the administrative board |
| William Winters | Member of the administrative board |
| Hans Jörg Reinhardt | Chairman of the administrative board |